Se den fullstendige veiledningen for mer informasjon, inkludert hva kanadiere bør gjøre og Health Canadas arbeid for å løse problemet med azido-urenheter som finnes i visse legemidler.
| Produkt | Organisasjon | DIN | Lot | utløps~~POS=TRUNC |
| MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389657 | 2005006959 | april 2023 |
| MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389657 | 2005006960 | april 2023 |
| MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389657 | 2005006961 | april 2023 |
| MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389657 | 2005006962 | april 2023 |
| MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389657 | 2005006963 | april 2023 |
| MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389657 | 2005011154 | juni 2023 |
| MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389657 | 2005011156 | juni 2023 |
| MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389665 | 2005006807 | april 2022 |
| MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389665 | 2005006808 | april 2022 |
| MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389665 | 2005006809 | april 2022 |
| MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389665 | 2005006810 | april 2022 |
| MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389665 | 2105002149 | desember 2022 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 1805012687 | oktober 2021 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 1805012688 | oktober 2021 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 1805012689 | oktober 2021 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 1805012792 | oktober 2021 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 1905001010 | desember 2021 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 1905001011 | desember 2021 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2005006947 | april 2023 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2005006949 | april 2023 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2005006950 | april 2023 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2005006951 | april 2023 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2005007297 | april 2023 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2005007298 | april 2023 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2005013776 | august 2023 |
| MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETTER | Mint Pharmaceuticals Inc. | 02389673 | 2105002150 | desember 2023 |
HVA SKAL TA BORT FRA DENNE ARTIKKELEN:
- 023896732005006947April 2023MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETSMint Pharmaceuticals Inc.
- 023896732005006949April 2023MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETSMint Pharmaceuticals Inc.
- 023896732005006950April 2023MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETSMint Pharmaceuticals Inc.
